Plain-English translation of NCT02682927 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a liquid medication given twice daily, to see if it could help reduce seizures in children and young adults with Dravet syndrome. Researchers studied two different doses of the medication, plus a placebo (inactive treatment), to understand which dose worked best and was safest. The trial involved over 260 young people across North America, Europe, Asia, and Australia.
Dravet syndrome is a severe form of childhood epilepsy where seizures often cannot be fully controlled by existing medications. This trial investigated whether this medication could offer additional help to young people who were still having breakthrough seizures despite being on other anti-seizure drugs.
Participants were randomly assigned to receive one of two doses of the liquid medication or a placebo, given twice daily with food. Over a 14-day period, participants gradually increased to their assigned dose, then continued at that dose for 12 weeks. During the trial, families kept detailed seizure records and attended regular study visits where doctors monitored heart health and safety. After the 12-week treatment period ended, participants gradually tapered off the medication over 2 weeks (unless they enrolled in a follow-up study).
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States